Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.7M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
49.9M
-
Shares change
-
+264K
-
Total reported value, excl. options
-
$984M
-
Value change
-
+$4.35M
-
Put/Call ratio
-
4.5
-
Number of buys
-
61
-
Number of sells
-
-47
-
Price
-
$19.68
Significant Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q1 2025
133 filings reported holding ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2025.
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.9M shares
of 59.7M outstanding shares and own 83.5% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.96M shares), FMR LLC (6.61M shares), COMMODORE CAPITAL LP (4.68M shares), VR ADVISER, LLC (4.03M shares), Fairmount Funds Management LLC (3.2M shares), BlackRock, Inc. (3M shares), Polar Capital Holdings Plc (2.37M shares), VANGUARD GROUP INC (1.97M shares), JANUS HENDERSON GROUP PLC (1.57M shares), and 5AM Venture Management, LLC (1.32M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.